LT2825558T - Derinių terapija, skirta kiaušidžių vėžiui gydyti - Google Patents

Derinių terapija, skirta kiaušidžių vėžiui gydyti

Info

Publication number: LT2825558T
Authority: LT; Lithuania
Prior art keywords: cancer; oven; treatment; combination therapy; therapy
Prior art date: 2012-03-13

Application number

LTEP13708435.6T

Other languages

English (en)

Inventor

Corrado Bernasconi

David BOLLAG

Original Assignee

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-13

Filing date

2013-03-11

Publication date

2019-08-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2825558(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-11 Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag

2019-08-12 Publication of LT2825558T publication Critical patent/LT2825558T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q90/00—Systems or methods specially adapted for administrative, commercial, financial, managerial or supervisory purposes, not involving significant data processing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Business, Economics & Management (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
General Physics & Mathematics (AREA)
Bioinformatics & Cheminformatics (AREA)
Strategic Management (AREA)
Finance (AREA)
Development Economics (AREA)
Economics (AREA)
Physics & Mathematics (AREA)
General Business, Economics & Management (AREA)
Accounting & Taxation (AREA)
Theoretical Computer Science (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Marketing (AREA)
Game Theory and Decision Science (AREA)
Entrepreneurship & Innovation (AREA)
Reproductive Health (AREA)
Dispersion Chemistry (AREA)

LTEP13708435.6T 2012-03-13 2013-03-11 Derinių terapija, skirta kiaušidžių vėžiui gydyti LT2825558T (lt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261610128P	2012-03-13	2012-03-13
US201261653598P	2012-05-31	2012-05-31
US201261672987P	2012-07-18	2012-07-18
PCT/EP2013/054818 WO2013135602A2 (en)	2012-03-13	2013-03-11	Combination therapy for the treatment of ovarian cancer

Publications (1)

Publication Number	Publication Date
LT2825558T true LT2825558T (lt)	2019-08-12

Family

ID=47844333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP13708435.6T LT2825558T (lt)	2012-03-13	2013-03-11	Derinių terapija, skirta kiaušidžių vėžiui gydyti

Country Status (32)

Country	Link
US (2)	US20150098988A1 (lt)
EP (2)	EP3553083A1 (lt)
JP (2)	JP6563197B2 (lt)
KR (1)	KR102082363B1 (lt)
CN (1)	CN104334577A (lt)
AR (1)	AR090313A1 (lt)
AU (2)	AU2013231410B2 (lt)
BR (1)	BR112014018964A2 (lt)
CA (2)	CA2860941C (lt)
CO (1)	CO7000770A2 (lt)
CR (1)	CR20140400A (lt)
CY (1)	CY1121821T1 (lt)
DK (1)	DK2825558T3 (lt)
EA (1)	EA201400996A1 (lt)
ES (1)	ES2736030T3 (lt)
HK (1)	HK1202122A1 (lt)
HR (1)	HRP20191248T1 (lt)
HU (1)	HUE045445T2 (lt)
IL (2)	IL234174B (lt)
LT (1)	LT2825558T (lt)
MX (1)	MX365139B (lt)
PE (1)	PE20141909A1 (lt)
PH (1)	PH12014501543A1 (lt)
PL (1)	PL2825558T3 (lt)
PT (1)	PT2825558T (lt)
RS (1)	RS58964B1 (lt)
SG (1)	SG11201404417PA (lt)
SI (1)	SI2825558T1 (lt)
SM (1)	SMT201900389T1 (lt)
TW (1)	TW201343178A (lt)
WO (1)	WO2013135602A2 (lt)
ZA (1)	ZA201404843B (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2758073B1 (en)	2011-09-23	2018-10-31	OncoMed Pharmaceuticals, Inc.	Vegf/dll4 binding agents and uses thereof
WO2013135602A2 (en)	2012-03-13	2013-09-19	F. Hoffmann-La Roche Ag	Combination therapy for the treatment of ovarian cancer
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
JP6967003B2 (ja) *	2015-09-23	2021-11-17	メレオバイオファーマ５インコーポレイテッド	がんの処置のための方法および組成物
WO2017117464A1 (en)	2015-12-30	2017-07-06	Kodiak Sciences Inc.	Antibodies and conjugates thereof
US20200121703A1 (en) *	2017-06-26	2020-04-23	The Cleveland Clinic Foundation	Cancer treatment
EP3758737A4 (en)	2018-03-02	2022-10-12	Kodiak Sciences Inc.	IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
EP4041312A4 (en)	2019-10-10	2023-12-20	Kodiak Sciences Inc.	METHOD FOR TREATING AN EYE DISORDER
CN115814076A (zh) *	2021-07-01	2023-03-21	江苏先声药业有限公司	抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
CN117940164A (zh) *	2022-04-26	2024-04-26	石药集团中奇制药技术（石家庄）有限公司	米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en)	1991-03-29	2003-11-06	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
CA2103059C (en)	1991-06-14	2005-03-22	Paul J. Carter	Method for making humanized antibodies
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
EP0666868B2 (en)	1992-10-28	2006-06-14	Genentech, Inc.	Use of anti-VEGF antibodies for the treatment of cancer
US5635388A (en)	1994-04-04	1997-06-03	Genentech, Inc.	Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11510170A (ja)	1995-07-27	1999-09-07	ジェネンテックインコーポレーテッド	タンパク質の処方
US6100071A (en)	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7365166B2 (en)	1997-04-07	2008-04-29	Genentech, Inc.	Anti-VEGF antibodies
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
DK0973804T3 (da)	1997-04-07	2007-05-07	Genentech Inc	Anti-VEGF-antistoffer
ES2256935T3 (es)	1997-04-07	2006-07-16	Genentech, Inc.	Anticuerpos humanizadores y procedimiento para producirlos.
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
ATE531812T1 (de)	1997-12-05	2011-11-15	Scripps Research Inst	Humanisierung von nager-antikörpern
EP1140173B2 (en)	1998-12-22	2013-04-03	Genentech, Inc.	Vascular endothelial cell growth factor antagonists and uses thereof
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
WO2001044463A1 (en)	1999-12-15	2001-06-21	Genentech, Inc.	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
CN101940189A (zh)	2000-11-30	2011-01-12	米德列斯公司	用于生产人类抗体的转基因转染色体啮齿动物
IL149701A0 (en)	2001-05-23	2002-11-10	Pfizer Prod Inc	Use of anti-ctla-4 antibodies
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
US20050079574A1 (en)	2003-01-16	2005-04-14	Genentech, Inc.	Synthetic antibody phage libraries
CN1829741A (zh)	2003-05-30	2006-09-06	健泰科生物技术公司	利用抗－vegf抗体的治疗
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en)	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
BRPI0508761A (pt)	2004-03-31	2007-08-14	Genentech Inc	anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
SV2006002143A (es) *	2004-06-16	2006-01-26	Genentech Inc	Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US20060009360A1 (en)	2004-06-25	2006-01-12	Robert Pifer	New adjuvant composition
HUE039591T2 (hu)	2004-09-03	2019-01-28	Genentech Inc	Humanizált anti-béta7 antagonisták és alkalmazásaik
US20070166388A1 (en) *	2005-02-18	2007-07-19	Desai Neil P	Combinations and modes of administration of therapeutic agents and combination therapy
EP1957531B1 (en)	2005-11-07	2016-04-13	Genentech, Inc.	Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en)	2005-12-02	2008-10-01	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
TW200812616A (en)	2006-05-09	2008-03-16	Genentech Inc	Binding polypeptides with optimized scaffolds
AU2007335744A1 (en) *	2006-12-20	2008-06-26	Alberto A. Gabizon	Method for administration of pegylated liposomal doxorubicin
CA2675451A1 (en)	2007-02-01	2008-07-08	Genentech, Inc.	Combination therapy with angiogenesis inhibitors
CN100592373C (zh)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	液晶显示面板驱动装置及其驱动方法
US20110159080A1 (en) *	2008-06-03	2011-06-30	Colin Lowery	Composition comprising liposome-entrapped doxorubicin and methods of administration
HUE024872T2 (en)	2008-11-22	2016-02-29	Hoffmann La Roche	Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
US20190185555A1 (en)	2017-12-19	2019-06-20	Genentech, Inc.	Anti-angiogenesis therapy for the treatment of previously treated breast cancer
CN110227154A (zh)	2010-02-23	2019-09-13	霍夫曼-拉罗奇有限公司	用于治疗卵巢癌的抗血管发生疗法
WO2013135602A2 (en)	2012-03-13	2013-09-19	F. Hoffmann-La Roche Ag	Combination therapy for the treatment of ovarian cancer

2013
- 2013-03-11 WO PCT/EP2013/054818 patent/WO2013135602A2/en active Application Filing
- 2013-03-11 SI SI201331522T patent/SI2825558T1/sl unknown
- 2013-03-11 AU AU2013231410A patent/AU2013231410B2/en active Active
- 2013-03-11 SG SG11201404417PA patent/SG11201404417PA/en unknown
- 2013-03-11 HU HUE13708435A patent/HUE045445T2/hu unknown
- 2013-03-11 KR KR1020147024773A patent/KR102082363B1/ko active IP Right Review Request
- 2013-03-11 JP JP2014561385A patent/JP6563197B2/ja active Active
- 2013-03-11 CA CA2860941A patent/CA2860941C/en active Active
- 2013-03-11 RS RS20190846A patent/RS58964B1/sr unknown
- 2013-03-11 US US14/384,863 patent/US20150098988A1/en not_active Abandoned
- 2013-03-11 CN CN201380024869.3A patent/CN104334577A/zh active Pending
- 2013-03-11 MX MX2014010591A patent/MX365139B/es active IP Right Grant
- 2013-03-11 BR BR112014018964-1A patent/BR112014018964A2/pt not_active Application Discontinuation
- 2013-03-11 CA CA3056813A patent/CA3056813A1/en not_active Abandoned
- 2013-03-11 PE PE2014001409A patent/PE20141909A1/es not_active Application Discontinuation
- 2013-03-11 LT LTEP13708435.6T patent/LT2825558T/lt unknown
- 2013-03-11 ES ES13708435T patent/ES2736030T3/es active Active
- 2013-03-11 PL PL13708435T patent/PL2825558T3/pl unknown
- 2013-03-11 PT PT13708435T patent/PT2825558T/pt unknown
- 2013-03-11 DK DK13708435.6T patent/DK2825558T3/da active
- 2013-03-11 EA EA201400996A patent/EA201400996A1/ru unknown
- 2013-03-11 SM SM20190389T patent/SMT201900389T1/it unknown
- 2013-03-11 EP EP19174209.7A patent/EP3553083A1/en active Pending
- 2013-03-11 EP EP13708435.6A patent/EP2825558B1/en active Active
- 2013-03-12 AR ARP130100793 patent/AR090313A1/es unknown
- 2013-03-12 TW TW102108775A patent/TW201343178A/zh unknown
2014
- 2014-06-27 CO CO14139058A patent/CO7000770A2/es not_active Application Discontinuation
- 2014-06-30 ZA ZA2014/04843A patent/ZA201404843B/en unknown
- 2014-07-03 PH PH12014501543A patent/PH12014501543A1/en unknown
- 2014-08-18 IL IL234174A patent/IL234174B/en active IP Right Grant
- 2014-08-26 CR CR20140400A patent/CR20140400A/es unknown
2015
- 2015-03-11 HK HK15102494.0A patent/HK1202122A1/xx unknown
2016
- 2016-05-12 US US15/153,637 patent/US11384142B2/en active Active
2017
- 2017-11-10 AU AU2017258927A patent/AU2017258927A1/en not_active Abandoned
2018
- 2018-07-13 JP JP2018132869A patent/JP6640288B2/ja active Active
- 2018-12-18 IL IL263781A patent/IL263781A/en unknown
2019
- 2019-07-11 HR HRP20191248TT patent/HRP20191248T1/hr unknown
- 2019-07-16 CY CY20191100758T patent/CY1121821T1/el unknown

Also Published As

Publication number	Publication date
MX2014010591A (es)	2014-09-18
KR102082363B1 (ko)	2020-02-27
TW201343178A (zh)	2013-11-01
IL263781A (en)	2019-01-31
CO7000770A2 (es)	2014-07-21
ZA201404843B (en)	2015-08-26
EA201400996A1 (ru)	2015-03-31
AU2017258927A1 (en)	2017-11-30
PL2825558T3 (pl)	2019-11-29
JP6640288B2 (ja)	2020-02-05
ES2736030T3 (es)	2019-12-23
CR20140400A (es)	2014-10-07
PH12014501543A1 (en)	2014-10-08
CN104334577A (zh)	2015-02-04
WO2013135602A2 (en)	2013-09-19
MX365139B (es)	2019-05-24
EP2825558B1 (en)	2019-05-15
KR20140138691A (ko)	2014-12-04
JP2015511593A (ja)	2015-04-20
US20160289317A1 (en)	2016-10-06
SI2825558T1 (sl)	2019-08-30
IL234174B (en)	2019-01-31
US20150098988A1 (en)	2015-04-09
DK2825558T3 (da)	2019-07-22
JP6563197B2 (ja)	2019-08-21
US11384142B2 (en)	2022-07-12
BR112014018964A8 (pt)	2017-07-11
CY1121821T1 (el)	2020-10-14
EP2825558A2 (en)	2015-01-21
HUE045445T2 (hu)	2019-12-30
SMT201900389T1 (it)	2019-09-09
EP3553083A1 (en)	2019-10-16
HK1202122A1 (en)	2015-09-18
HRP20191248T1 (hr)	2019-10-18
WO2013135602A3 (en)	2013-11-07
JP2018193380A (ja)	2018-12-06
AR090313A1 (es)	2014-11-05
BR112014018964A2 (pt)	2020-05-12
CA3056813A1 (en)	2013-09-19
CA2860941A1 (en)	2013-09-19
SG11201404417PA (en)	2014-10-30
PE20141909A1 (es)	2014-11-29
PT2825558T (pt)	2019-07-11
RS58964B1 (sr)	2019-08-30
KR102082363B9 (ko)	2023-05-02
AU2013231410A1 (en)	2014-07-17
AU2013231410B2 (en)	2017-08-17
CA2860941C (en)	2019-11-05

Publication	Publication Date	Title
IL289300A (en)	2022-02-01	Combined treatment for cancer
HRP20190046T1 (hr)	2019-05-03	Kombinirana terapija za liječenje raka
HUE057061T2 (hu)	2022-04-28	Kombinációs terápia rák kezelésére
IL245731A0 (en)	2016-07-31	Combined treatment for cancer
HK1221408A1 (zh)	2017-06-02	用於治療成膠質細胞瘤的組合療法
IL263661A (en)	2019-01-31	Combination therapy for the treatment of glioblastoma
HK1211210A1 (zh)	2016-05-20	治療多發性硬化症的組合療法
LT2825558T (lt)	2019-08-12	Derinių terapija, skirta kiaušidžių vėžiui gydyti
LT2914254T (lt)	2020-04-27	Kombinacinės terapijos chemoresistencinių vėžių gydymui
SI2892925T1 (sl)	2020-11-30	Kombinacijsko zdravljenje raka
PL2855475T3 (pl)	2018-02-28	Alfa-karboliny do leczenia nowotworu
IL233495A0 (en)	2014-08-31	Combination for cancer treatment
GB201317564D0 (en)	2013-11-20	Therapeutic for the treatment of Lung Cancer
GB201222949D0 (en)	2013-01-30	Combination Treatment of Cancer
GB201222950D0 (en)	2013-01-30	Combination treatment of cancer